ArticleInternational journal of molecular medicine2019
Metformin prevents nephrolithiasis formation by inhibiting the expression of OPN and MCP-1 in vitro and in vivo.
Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Comment on "Comparison of 24-Hour urine parameters before and after initiation of metformin in patients with diabetes and urolithiasis: A retrospective analysis".Urolithiasis · 2026Article
- Comparison of 24-Hour urine parameters before and after initiation of Metformin in patients with diabetes and urolithiasis: A retrospective analysis.Urolithiasis · 2025Article
- Research progress on the mechanisms of interleukin and chemokine families in driving calcium oxalate nephrolithiasis formation.Frontiers in immunology · 2025Review
- Kidney Stones of Type I vs. Type II Diabetic Patients: Are There Any Differences?Journal of clinical medicine · 2024Article
- Review
- Inflammation-associated ectopic mineralization.Fundamental research · 2023Review
- Cellular distribution of C-C motif chemokine ligand 2 like immunoreactivities in frontal cortex and corpus callosum of normal and lipopolysaccharide treated animal.BMC neuroscience · 2022Article
- Is metformin use associated with changes in urinary parameters in stone formers?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Association between body fat distribution and kidney stones: Evidence from a US population.Frontiers in endocrinology · 2022Article
- Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment targeting osteopontin (OPN) and monocyte chemoattractant protein 1 (MCP‑1) has been recognized as a novel approach in renal crystal formation. The present study was designed to investigate the suppressive effects of metformin on nephrolithiasis formation and its potential mechanism. The cytotoxicity of metformin on MDCK and HK‑2 cells was determined using a Cell Counting Kit‑8 assay in vitro. Subsequently, the mRNA transcription and protein expression levels of MCP‑1 and OPN were detected by reverse transcription‑quantitative‑polymerase chain reaction analysis, western blot analysis and ELISA. Male Sprague‑Dawley rats were divided into a control group, ethylene glycol (EG) group and EG + metformin group. The expression levels of MCP‑1 and OPN and crystal formations were evaluated in renal tissues following an 8‑week treatment period. In vitro, metformin significantly inhibited the production of MCP‑1 and OPN induced by oxalate at the mRNA and protein expression levels. In vivo, increased expression levels of MCP‑1 and OPN were detected in the EG group compared with the controls, and this upregulation was reversed in the EG + metformin group. Renal crystal deposition in the EG + metformin group was markedly decreased compared with that in the EG group. Therefore, the results of the study suggest that metformin suppressed urinary crystal deposit formation, possibly by mediating the expression of inflammatory mediators OPN and MCP‑1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.